Environmental

BMY’s R&D intensity supports a lower-carbon, science-based operating model versus peers, but the benefit is indirect because pharmaceuticals are already relatively light on direct emissions.

The company’s capital allocation toward research rather than heavy manufacturing capex reduces environmental footprint risk versus more asset-intensive healthcare peers, though supply-chain emissions remain material.

No provided metrics indicate superior energy, water, or waste performance, so BMY’s environmental positioning appears broadly in line with large-cap pharma peers rather than clearly leading.

Relative to peers, BMY’s environmental profile is helped more by industry structure than by disclosed operational outperformance, limiting upside to a moderate score.

Social

BMY’s high R&D spend supports patient-focused innovation and access to new therapies, which is a core social strength versus peers with weaker pipeline investment.

The company’s low stock-based compensation as a share of revenue suggests less dilution pressure and may indicate more restrained pay practices than some large-cap peers.

As a major pharmaceutical company, BMY faces elevated product-safety, access, and pricing scrutiny, but these risks are industry-wide and not clearly worse than peers from the data provided.

Relative to peers, BMY appears socially solid because its business model centers on health outcomes, while no provided metrics suggest a material labor or community disadvantage.

Governance

BMY’s leverage is elevated versus a conservative balance-sheet profile, which can constrain governance flexibility and increase oversight pressure relative to stronger peers.

Net debt to EBITDA remains manageable, but the debt load is still meaningful for a large-cap pharma issuer and leaves less room than lower-levered peers.

Low stock-based compensation supports better alignment than peers with heavier equity dilution, and the current leverage profile is manageable but still not a standout governance advantage.

Overall governance looks average to slightly below top-tier peers because balance-sheet leverage remains the main structural weakness, despite reasonable compensation discipline.

Overall Score

BMY’s ESG profile is supported by strong R&D-led social positioning and acceptable environmental characteristics, while leverage remains a constraint but looks manageable enough to lift the overall profile slightly.

Score Driver: Elevated Leverage Relative To Peers